- Positive results from Pyratine XR(TM) rosacea-specific study also slated for presentation at American Academy of Dermatology Meeting on March 8, 2009 -
NAPA, Calif., March 5 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging, announced today that Pyratine XR(TM) is officially launching at the American Academy of Dermatology's 67th Annual Meeting in San Francisco, March 6-10, 2009, at Booth #5736. In addition, positive study results from a clinical trial of Pyratine XR(TM) in patients with rosacea will be presented.
Dr. Arisa Ortiz, Clinical Research Fellow in the Department of Dermatology at the
The rosacea-specific study data demonstrated that Pyratine XR(TM) showed continual improvement for all of the major symptoms of rosacea - redness, lesions and spider veins - throughout the entire course of 48-week treatment period. This suggests that Pyratine XR(TM) may offer important advantages over currently available treatments for rosacea, many of which have issues with long-term tolerability. Since rosacea is a chronic condition that often requires extended treatment periods with topical agents that can cause high skin sensitivity, treatments that provide sustained relief of the signs and symptoms of rosacea are needed.
Eighteen subjects with mild-to-moderate rosacea participated in a 48-week clinical trial at the
|SOURCE Senetek PLC|
Copyright©2009 PR Newswire.
All rights reserved